### Highlights of This Issue

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1187</td>
</tr>
</tbody>
</table>

### Special Features

#### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1189</td>
</tr>
</tbody>
</table>

**PET Imaging of Tumor Growth: Not as Easy as It Looks**

Anthony F. Shields  
*See article p. 1303*

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1192</td>
</tr>
</tbody>
</table>

**Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety**

David L. Bajor and Robert H. Vonderheide  
*See article p. 1386*

#### CCR New Strategies

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1195</td>
</tr>
</tbody>
</table>

**New Strategies in Melanoma: Molecular Testing in Advanced Disease**

Scott E. Woodman, Alexander J. Lazar, Kenneth D. Aldape, and Michael A. Davies  
*See article p. 1368*

#### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1201</td>
</tr>
</tbody>
</table>

**Molecular Pathways: Beta-Adrenergic Signaling in Cancer**  
Steven W. Cole and Anil K. Sood  
*See article p. 1344*

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1207</td>
</tr>
</tbody>
</table>

**Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer**

Asis Palazón, Julián Aragónés, Aíza Morales-Kastresana, Manuel Ortiz de Landázuri, and Ignacio Melero  
*See article p. 1354*

#### Review

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1214</td>
</tr>
</tbody>
</table>

**Here, There Be Dragons: Charting Autophagy-Related Alterations in Human Tumors**

Chandra B. Lebovitz, Svetlana B. Bortnik, and Sharon M. Gorski  
*See article p. 1360*

### Cancer Therapy: Preclinical

**Activation of PI3K Signaling in Merkel Cell Carcinoma**

Valentina Nardi, Youngchul Song, Juan A. Santamaria-Barría, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, Vanessa L. Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Ryan, Darrell B. Borger, Atul K. Bhan, Mai P. Hoang, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, and Dora Dias-Santagata  
*See article p. 1360*

**Infiltration of Lynch Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph Node Metastases**

*See article p. 1360*

**HDL of Patients with Type 2 Diabetes Mellitus Elevates the Capability of Promoting Breast Cancer Metastasis**

Bing Pan, Hui Ren, Yubin He, Xiaofeng Lv, Yijing Ma, Jing Li, Li Huang, Baoqi Yu, Jian Kong, Chenguang Niu, Youyi Zhang, Wen-bing Sun, and Lemin Zheng  
*See article p. 1360*

**Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival**

Evgenia Gubanova, Brandee Brown, Sergei V. Ivanov, Thomas Helleday, Gordon B. Mills, Wendell G. Yarbrough, and Natalia Issaeva  
*See article p. 1360*

**Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb**

Takeshi Miyazaki, Yang Pan, Kaushal Joshi, Deepti Purohit, Bin Hu, Habibe Demir, Sarmistha Mazumder, Sachiko Okabe, Takao Yamori, Mariano Viapiano, Kazuo Shin-ya, Hiroyuki Seimiya, and Ichiro Nakano  
*See article p. 1360*
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
</table>
| 1281 | **SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer**  
Won Gu Kim, Celine J. Guigon, Laura Fozzatti, Jeong Won Park, Changxue Lu, Mark C. Willingham, and Sheue-yann Cheng |
| 1291 | **Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma**  
Yang Xu, Venugopal Chenna, Chaoxin Hu, Hai-Xiang Sun, Mehtab Khan, Haibo Bai, Xin-Rong Yang, Qin-Feng Zhu, Yun-Fan Sun, Anirban Maitra, Jia Fan, and Robert A. Anders |
| 1303 | **[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells**  
Cathy C. Zhang, Zhengming Yan, Wenlin Li, Kyle Kuszpit, Cory L. Painter, Qin Zhang, Patrick B. Lappin, Tim Nichols, Maruja E. Lira, Timothy Affolter, Neeta R. Fahey, Carleen Cullinane, Mary Spilker, Kenneth Zasadny, Peter O'Brien, Dana Buckman, Anthony Wong, and James G. Christensen |
| 1313 | **Epidermal Growth Factor Receptor Protein Detection in Head and Neck Cancer Patients: A Many-Faceted Picture**  
Juliette Thariat, Marie-Christine Etienne-Grimaldi, Dominique Grall, René-Jean Bensadoun, Anne Cayre, Frédérique Penault-Llorca, Laurence Veracini, Mireille Francoual, Jean-Louis Formento, Olivier Dassonneville, Dominique De Raucourt, Lionel Geoffrois, Philippe Giraud, Séverine Racadot, Sylvain Mortinière, Gérard Milano, and Ellen Van Obberghen-Schilling |
| 1323 | **Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer**  
Markus Riester, Jennifer M. Taylor, Andrew Feifer, Theresa Koppie, Jonathan E. Rosenberg, Robert J. Downey, Bernard H. Bochner, and Franziska Michor |
| 1334 | **Copy Number Losses Define Subgroups of Dedifferentiated Liposarcoma with Poor Prognosis and Genomic Instability**  
Aimee M. Crago, Nicholas D. Socci, Penelope DeCarolli, Rachael O’Connor, Barry S. Taylor, Li-Xuan Qin, Cristina R. Antonescu, and Samuel Singer |
| 1341 | **Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling**  
Hatem A. Azim Jr, Stefan Michiels, Philippe L. Bedard, Sandeep K. Singhal, Carmen Criscitiello, Michail Ignatiadis, Benjamin Haibe-Kains, Martine J. Piccart, Christos Sotiriou, and Sherene Loi |
| 1352 | **Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer**  
Timothy R. Donahue, Linh M. Tran, Reginald Hill, Yunfeng Li, Anne Kovochich, Joseph H. Calvopina, Sanjeet G. Patel, Nanping Wu, Anreas Hindoyan, James J. Farrell, Xinmin Li, David W. Dawson, and Hong Wu |
| 1364 | **Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)- Branched Oligosaccharides as a Marker of Tumor Progression**  
Tobias Lange, Sebastian Ultrich, Imke Müller, Michael F. Nentwich, Katrin Stübke, Susanne Feldhaus, Christine Knes, Olaf J.C. Hellwinkel, Robert L. Vessella, Claudia Abramjuk, Mario Anders, Jennifer Schröder-Schwarz, Thorsten Schlimm, Hartwig Huland, Guido Sauter, and Udo Schumacher |
| 1374 | **High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway**  
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, and Richard A. Scolyer
See commentary p. 1192

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Andres Forero-Torres, Sven de Vos, Brad L. Pohlmans, Maksim Pashkevich, Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, James G. Nelson, Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, and Kristen N. Ganjoo

Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
David S. Yoo, John P. Kirkpatrick, Oma Craciunescu, Gloria Broadwater, Bercedis L. Peterson, Madeline D. Carroll, Robert Clough, James R. MacFall, Jenny Hoang, Richard L. Scher, Ramon M. Esclamado, Frank R. Dunphy, Neal E. Ready, and David M. Brizel

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma
Kensuke Aoe, Vishwa Jeet Amatys, Nobukazu Fujimoto, Kei Ohnuma, Osamu Hosono, Akio Hiraki, Masanori Fujii, Taketo Yamada, Nam H. Dang, Yukio Takeshima, Kouki Inai, Takumi Kishimoto, and Chikao Morimoto

Sunitinib Therapy for Melanoma Patients with KIT Mutations
David R. Minor, Mohammed Kashani-Sabet, Maria Garrido, Steven J. O’Day, Omid Hamid, and Boris C. Bastian

Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer
Julie K. Schwarz, Jacqueline E. Payton, Ramachandran Rashmi, Tao Xiang, Yunhe Jia, Phyllis Huettner, Buck E. Rogers, Qin Yang, Mark Watson, Janet S. Rader, and Perry W. Grigsby

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
Robert C. Doebele, Amanda B. Pilling, Dara L. Aisner, Tatianna G. Kutateladze, Anh T. Le, Andrew J. Weickhardt, Kimi L. Kondo, Derek J. Linderman, Lynn E. Heasley, Wilbur A. Franklin, Mariella Varela-Garcia, and D. Ross Camidge

Correction: Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes

Correction: Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies
ABOUT THE COVER

Following treatment with a G-quadruplex ligand, telomestatin, glioma stem cells rapidly developed punctate nuclear 53BP1 foci. Of note, some of these foci colocalized with nontelomeric DNA, thereby representing both telomeric and nontelomeric dysfunction-induced foci, a hallmark of deprotected DNA damage. The loss of tumor stemness is likely associated with a failure in the DNA damage response elicited by telomestatin in glioma stem cells. For details, see the article by Miyazaki and colleagues on page 1268 of this issue.